Smith & Nephew Stock Price, News & Analysis

Smith+Nephew (NYSE:SNN) announces the launch of DOUBLEFLO Inflow/Outflow Pump and 4KO (Optimized) Arthroscopes and Laparoscopes, enhancing the INTELLIO Connected Tower Solution. The DOUBLEFLO Pump is remotely controllable, allowing surgeons to focus on patients during procedures. The 4KO Scopes promise a 30% increase in image resolution, supporting multi-specialty centers. Both products are now available in the US and Europe, aimed at improving surgical performance and capital investment value.

Smith+Nephew (LSE:SN, NYSE:SNN) announced that its LEAF Patient Monitoring System has monitored over 60,000 patients, accumulating more than 7 million hours of use. This system aims to reduce hospital-acquired pressure injuries (HAPIs), which have risen in the U.S., costing an average of $21,767 per patient. Clinical trials indicated a 73% reduction in HAPI odds, potentially saving up to $39 billion nationally. By implementing the LEAF System, healthcare facilities have raised patient repositioning adherence from under 50% to as high as 98%, enhancing patient care and reducing costs.

Smith+Nephew (LSE:SN, NYSE:SNN) has announced a marketing collaboration with Movendo Technology to enhance its Real Intelligence ecosystem with personalized robotic rehabilitation capabilities. This collaboration, initiated in Europe, focuses on Movendo's HUNOVA rehabilitation device, which analyzes biomechanics to create individualized recovery programs. This partnership aims to improve patient outcomes through integrated robotics-assisted surgery and rehabilitation. The CORI Surgical System will also launch in Europe after its successful introduction in the U.S. in 2020.

Smith+Nephew (NYSE:SNN) announced a real-world study from Spain showing that their ALLEVYN LIFE Foam Dressings significantly reduced dressing change frequency by 47.1% and weekly dressing costs by 58.7%. Conducted across 24 primary care centers and six nursing homes, the study included 94 patients with a median age of over 70. Healthcare professionals noted improved patient satisfaction and treatment experiences despite fewer nursing visits, showcasing ALLEVYN LIFE's effective exudate management and cost efficiency in wound care.

Smith+Nephew (LSE:SN, NYSE:SNN) announced a new publication highlighting that its PICO Single Use Negative Pressure Wound Therapy System (sNPWT) reduces surgical site infections (SSIs) by 63%, seroma by 77%, and dehiscence by 30%. The systematic review covered 29 studies with 5,614 patients, demonstrating the therapy's efficiency across various surgical specialties. The PICO sNPWT also decreases hospital stay length by nearly 2 days, potentially benefiting healthcare systems significantly. This evidence supports PICO therapy for preventing surgical complications effectively.

Smith+Nephew (NYSE: SNN) has successfully launched a new inventory automation solution in partnership with Movemedical in the US. This platform aims to simplify field sales operations for better inventory management, ensuring timely product delivery to customers. The solution enhances logistics and real-time data access, empowering sales teams to meet customer needs effectively. Smith+Nephew integrated this system across its entire US Orthopaedic sales force in just over a week, highlighting its operational efficiency.

Smith+Nephew (LSE:SN, NYSE:SNN) has announced exceptional clinical outcomes for its total hip arthroplasty (THA) portfolio, achieving the highest implant survivorship of 98.46% at ten years in the National Joint Registry for England, Wales, and Northern Ireland. Their POLAR3 Total Hip Solution also boasts a 72% lower revision risk compared to the class average. Additionally, the Australian Orthopaedic Association Registry reported a 94.5% survivorship at 15 years with the proprietary OXINIUM Technology, which reduces revision risk by 39-41% compared to traditional options.

Smith+Nephew (NYSE:SNN) has launched RI.INSIGHTS, a pioneering platform aimed at enhancing robotics-assisted surgeries. This tool allows orthopedic surgeons to benchmark their surgical experiences against peers and utilize intra and post-operative data to improve patient outcomes. The platform, part of the Real Intelligence portfolio, aims to drive advancements in digital health and robotics surgery. Currently available on a limited basis, a full commercial release is planned for 2021. Smith+Nephew generated $5.1 billion in sales in 2019, emphasizing its commitment to innovation in orthopedic technology.

Smith+Nephew (NYSE:SNN) announced positive two-year follow-up results from the STITCH Study for its NOVOSTITCH Meniscal Repair Systems. This first-of-its-kind trial demonstrated an impressive clinical success rate of 82.6%, with significant improvements in all Patient Reported Outcome Measures (PROMs) at p<0.001. Complete meniscal healing was observed in 100% of patients evaluated at six months. The study emphasizes a shift towards meniscal repair, which could prevent long-term complications like osteoarthritis associated with meniscectomy. The NOVOSTITCH system offers innovative solutions for complex meniscal tears.